Inhibitors that can block upstream or downstream elements in the EGFR signaling pathway have been extensively developed in cancer research over the past two decades because EGFR downstream signaling regulates tumor progression via proliferation, metastasis, angiogenesis, and drug resistance mechanisms. Here, EGFR is linked to cancer.